INTRODUCTION
Chromosomal aneuploidy or somatic copy number alterations (SCNAs) are frequently observed in malignant neoplasms including lung cancers and have been proposed to drive tumorigenesis or treatment resistance [1, 2] . SCNAs such as amplification of the mesenchymal-epithelial transition factor gene (MET) which resides on chromosome 7q31, can be detected conveniently by using fluorescence in situ hybridization (FISH) . MET amplification (METamp) has been associated with shorter overall survival (OS) in patients with non-small cell lung cancer (NSCLC) [3] [4] [5] [6] . Therefore, MET is considered a potentially targetable oncogenic driver [7, 8] . Recent studies have shown that amplified MET is a clinically valid therapeutic target for MET inhibitors or MET-tyrosine kinase inhibitors (e.g. crizotinib) approved recently for the treatment of patients with NSCLC [9] .
The frequency of METamp as detected by FISH in NSCLC is variable in the literature, ranging from 3% to 10%. This range in frequency is likely attributable to a lack of standardization of FISH techniques, different cutoffs for defining MET positivity, and/or patient selection criteria across studies [6, [10] [11] [12] [13] [14] [15] [16] . For example, in a study of 213 Asian patients with NSCLC, Okuda et al. [16] used a cutoff of 3 or more copies of MET per cell to define MET-FISH positivity. They reported that patients with MET-positive tumors had a shorter OS than did patients with a normal MET-FISH result. In contrast, Cappuzzo et al. [6] used a cutoff of 5 copies per cell to designate MET-FISH positivity because patients with 5 or more copies of MET showed a worse clinical outcomes than did those with fewer than 5 copies. In another study involving 141 patients with stage I lung adenocarcinoma, a mean MET copy number (MET-CN) ≥ 3.4 per cell was regarded as a positive result and was associated with a poorer prognosis [3] . In a recent study, Noonan and colleagues [17] proposed using a combination of criteria to establish MET-FISH positivity: a MET/CEP7 (centromeric probe of chromosome 7) ratio of ≥ 1.8 or a MET-CN ≥ 5. The variations among these studies indicate that the criteria used to define MET-FISH positivity are inconsistent and that researchers need to reach a consensus on a positive cutoff point above which MET-CN has a clinical impact on outcomes in patients with NSCLC [6, [10] [11] [12] [13] [14] [15] [16] .
Although preclinical studies have shown that tumor cells with METamp display significantly increased sensitivity to MET inhibitors or MET tyrosine kinase inhibitors (MET-TKIs) [18] [19] [20] , several clinical trials of MET inhibitors have failed in patients with METamp as determined by FISH [21] [22] [23] . One potential reason for the failure of these trials may be that MET-CN status cannot be assessed consistently or accurately because no standard MET-FISH reporting criteria is available. In addition, most clinical studies related to MET-CN status were conducted in NSCLC patients who had undergone surgical resection; very limited data are available on patients with unresectable stage IV disease [3, 6, 16] . Although one recent study population included about 60% stage IV patients, no detailed clinical data were provided [17] .
To improve patient selection criteria for trials of targeted MET inhibitors, we conducted a comprehensive retrospective review of MET-FISH data of NSCLC patients evaluated during a 6-year period. We evaluated and validated MET-FISH reporting criteria proposed in the literature and correlated MET-FISH results with clinical outcome and disease progression in NSCLC patients who presented without distant metastasis. We also used these data to suggest more optimized MET-FISH reporting criteria to facilitate accurate determination of clinically relevant MET-CN status and improve risk stratification of patients with NSCLC.
RESULTS

Clinicopathologic data
The study group included 384 NSCLC specimens tested for MET-CN. 
Optimization of MET-FISH reporting criteria
Patients were first stratified into 5 groups according to MET-CN and MET/CEP7 ratio (Groups 1-4 MET/CEP7 ratio < 2.0) and: Group 1 characterized by MET-CN < 3 (273 patients, 71.1%); Group 2 with MET-CN ≥ 3 to < 4 (65 patients, 16 When we tested for associations between these groups and OS in patients with stages I to III disease, we found that patients in Groups 1 and 2 had a similar median OS (48.9 months and 59.1 months, respectively; P =.321). Groups 4 and 5 also had similar OS (28.1 months vs. 23.6 months, respectively; P =.782). Patients in Groups 1 and 2 had markedly longer median OS than did patients in Groups 4 and 5. Interestingly, patients in Group 3 had significantly longer median OS than patients in any other group (134.4 months; P =.03) ( Figure 1A and Supplementary Table 2 ).
Because our OS data for patients with stages I-III disease were consistent with those of reported previously in a large study [6] , we next re-categorized the data using a MET-CN cutoff of 5 copies and a MET/CEP7 ratio cutoff of 2.0. These optimized MET-FISH reporting categories were as follows:
-METamp: (A) MET/CEP7 ratio ≥ 2.0, or (B) MET-CN ≥ 5, or (C) MET/CEP7 ratio < 2.0 but MET-CN ≥ 20 or MET signal clusters in more than10% of tumor cells.
-MET-CN-gain (METcng): MET/CEP7 ratio < 2.0 and MET-CN ≥ 4 to < 5.
-METneg: MET/CEP7 ratio < 2.0 and MET-CN < 4. We reclassified all cases into these 3 categories for further analyses of OS and risk stratification ( Figure 1B and Supplementary Table 2 ).
METamp is highly associated with stage IV NSCLC
The mean MET-CN in the overall study cohort was 3.1 copies per cell (range, 1.5 -20.5). The mean MET/ CEP7 ratio was 1.15 (range, 0.5 -8.5). The mean MET-CN and mean MET/CEP7 ratio were significantly higher in patients with stage IV NSCLC than in patients with stages I-III disease (P =.042 and P =.016, respectively) (Supplementary Table 3 ). Using the optimized MET-FISH reporting criteria, 29 of 384 (7.6%) patients were categorized as having METamp.
Among the 170 patients with stage I-III disease, 153 (90%) were in the METneg group, 10 (5.9%) in the METcng group, and 7 (4.1%) in the METamp group. Of the 214 patients with stage IV disease, 185 (86.4%) were in the METneg group and 7 (3.3%) in the METcng group. We determined that 22 (10.3%) patients with stage IV NSCLC had METamp, a significantly higher rate than that found in patients with stages I-III disease (P =.038), indicating that METamp was highly associated with advanced disease stage (Supplementary Table 3 and Table 2 ). Table 5 ). The overall concordance between the MET-FISH and the MET-IHC was 44.8% (P =.11) (Supplementary Table 5 ).
MET-FISH and MET-IHC correlations
METamp is associated with shorter OS in patients with stages I-III NSCLC
The median follow-up duration was 19.5 months and the median OS was 36.4 months for the overall study cohort. OS was not associated with patient age (P =.18), sex (P =.58), or race/ethnicity (P =.45). As expected, longer OS was highly associated with early-stage (I-III) disease (P <.001) and with adenocarcinoma (P <.001) (Supplementary Table 4 ).
Under the optimized MET-FISH reporting criteria, the median OS durations of early-stage patients with METamp, METcng, and METneg were 28.1, 134.4, and 51.6 months, respectively. Patients with METamp had significantly shorter OS than did patients with METneg (P =.036), and patients with METcng had longer OS than did patients with METneg, although the difference was not statistically significant (P =.109) ( Figure 1B , Table 3) In patients with stage IV tumors, MET-CN status showed no statistically significant association with OS ( Figures 1C and 1D , Table 4 ). However, patients with METcng did have substantially longer OS than did patients with METneg (66.2 vs. 17.5 months, P =.053). This pattern was similar to that observed in patients with stages I-III disease.
METamp is associated with earlier distant metastases in patients with stages I-III NSCLC
We assessed the relationship between MET-CN and disease metastases in patients with stages I-III NSCLC. The 7 patients with METamp tumors had a significantly shorter median time to distant metastasis (11.6 months) than did patients with METneg (43.8 months; P =.004) or METcng (37.0 months) tumors (Table 3 and Figure 2 ), indicating that METamp is a risk factor for earlier distant metastases in patients with NSCLC. Figure 2) . However, in patients with stage IV disease, METamp showed no significant impact on outcomes in either the univariate or the multivariate analyses (Table 4) .
METamp is an independent predictor of worse OS in patients with stages I-III NSCLC
MET overexpression assessed by IHC is not associated with clinical outcomes
Of 202 patients with MET-IHC data available, the median OS was 24.5 months in patients with The adenocarcinoma category also included bronchoalveolar histology. Non-adenocarcinoma included 26 patients with squamous cell carcinoma, 4 patients with unclassified non-small cell lung cancer, and 1 patient with adenosquamous carcinoma. * Indicates statistically significant result (P <.05).
MET overexpression versus 36.5 months observed in patients with a normal MET expression (P =.31). We further assessed the potential clinical impact of MET overexpression in patients with different disease stages. In 92 patients with stage I-III disease, the median OS was 51.6 months in those with tumors with normal MET expression (n = 41) versus 54.9 months in patients with tumors with MET overexpression (n = 51) (P =.97). In 110 patients with stage IV disease, the median OS was 16.3 months in those with tumors that showed normal MET expression (n = 37) versus 20.4 months in those patients with tumors with MET overexpression (n = 73) (P =.67) (Supplementary Figure 1) . Our data indicate that MET overexpression alone does not impact clinical outcome.
DISCUSSION
In this study, we evaluated data on MET-CN status in 384 NSCLC patients with various disease stages and identified associations between MET-CN and clinical outcome. To resolve the conflicting MET-FISH reporting criteria in the literature, we stratified our patient cohort into 5 groups based on MET-CN and MET/CEP7 ratio and identified associations between these groups and outcomes. We focused initially on patients with stage I-III tumors because METamp has been reported to be associated with stage IV tumors [6] . On the basis of overall survival, we optimized our MET-FISH reporting criteria by integrating MET-CN and MET/CEP7 ratio and reclassifying the patients into 3 groups: METamp, METcng, and METneg. These new, optimized criteria merged groups 4 and 5 (MET-CN ≥ 5 and MET/CEP7 ratio ≥ 2.0) into one group, METamp, because they had similar OS (Supplementary Table 1 ). These results were consistent with previous reports [6] . Moreover, patients with METcng (MET/CEP7 ratio < 2.0 and MET-CN ≥ 4 to < 5) had markedly better OS than did patients in the other groups, suggesting that patients with METcng constitute a distinct group of NSCLC patients. We also found that patients with METamp had a higher risk of distant metastasis than did patients in the other groups.
According to the MET-FISH reporting criteria we suggest, the overall frequency of METamp in this study cohort was about 8%. We noted that METamp was significantly more common in patients with stage IV disease than in patients without distant metastases. We confirmed that METamp was an independent risk factor for poor OS in patients with early-stage (I-III) NSCLC (28.1 months vs. 134.35 months in METcng and 51.6 months in METneg, P =.015), consistent with results reported previously [6] . Importantly, all patients with METamp and stage I-III disease in this study cohort developed distant metastases within 1 year of diagnosis, indicating that METamp status predicts early distant metastases in patients with stages I-III NSCLC. Although 34 patients in the stage I-III disease group were positive for EGFR mutation, when this subset was compared with those who had no EGFR mutations, there was no significant impact observed on OS or progression to distant metastasis.
Only limited clinical data have been published on MET-CN status and its clinical implications in patients with stage IV NSCLC [3, 6, 16] . In this study, 214 patients with stage IV disease were investigated. We found that METamp was highly associated with stage IV NSCLC, but did not further negatively impact clinical outcomes when compared with the METneg category for patients with the same disease stage. However, we found that patients with stage IV disease and METcng had much longer OS durations than did those with either METneg or METamp (66.2 months vs. 17.5 months in METneg vs. 22.8 months in METamp, P =.053).
The METcng category identified in this cohort likely represents a distinct group of NSCLC patients, similar to that identified by Cappuzzo et al. [6] , although that study classified patients with MET-CN ≥ 4 to < 5 as METneg and for that reason did not provide full clinical data for all patients. We speculate that the METcng category may represent patients with multiple polysomies e.g. neartetrasomies as indicated by the copy numbers. Most of the 17 METcng patients in this cohort, who presumably had near-tetrasomy of chromosome 7, also showed evidence of having near-tetrasomies of chromosomes 2 (by ALK-FISH), 6 (by ROS1-FISH), or 10 (by RET-FISH) (data not shown). METcng coinciding with CN gains of ALK, ROS1, and RET likely resulted from genomewide polysomies, particularly near-tetraploidy. Similar findings have been reported in a study of 47 patients with EGFR-negative lung cancer, in which 13 patients with polysomy 7 showed improved progression-free survival [25] . To further confirm the FISH findings, we performed OncoScan microarray (Affymetrix) on a subset of patients based on the availability of FFPE tumor blocks including 5 METcng samples. SNP array data showed an overall good concordance with FISH, and the normalized genomic profiles in cases with METcng showed significantly lower genomic copy number complexity comparing the METneg and METamp groups. Although our microarray sample number was small, such METcng cases with a low frequency of somatic copy number alterations (SCNAs) [1, 2] could be clinically less aggressive and likely associated with a better outcome, however, the underline mechanisms remain to be explored and a genome wide assessment of SCNAs in a large study is needed to confirm our findings. The adenocarcinoma category also included bronchoalveolar histology. Non-adenocarcinoma included 14 patients with squamous cell carcinoma and 1 patient with unclassified non-small cell lung cancer.
On the basis of these observations, we argue against treating patients who have METcng with MET inhibitors. Several clinical trials have failed to show any positive effect of MET inhibitors on patient survival. We speculate that these studies may have inaccurately identified patients with METcng as having METamp. For example, in one phase II study of 37 MET-positive patients [23] , MET positivity was defined as MET-CN ≥ 4 in over 40% of cells; only 3 of the 37 patients with a MET/CEP7 ratio > 2.0 would have been interpreted as having METamp using the criteria we suggest in this study. Similarly, in a phase III study, only 4 of 54 patients had a MET/CEP7 ratio > 2.0 [22] . We speculate that the patients enrolled in these two trials may have had METcng, not "real" METamp, and that this may explain the poorer response among these patients to MET inhibitors. Our results highlight the clinical importance of accurate MET-CN assessment using standardized and optimized reporting criteria in determining eligibility for clinical trials of MET inhibitors.
Cases with a MET-CN at the borderline of METneg and METcng (3.8-3.9) or of METcng and METamp (4.8-4.9) can be challenging for risk stratification, as some of these results could be explained by tumor heterogeneity which are not uncommon in many cancers. However, in such cases, the overall estimated copy numbers i.e. by FISH for the assessment of oncogene amplifications are often underestimated [26] . Using the definition of METamp in this study, the results are in line with what have been reported. In addition, using our suggested reporting criteria, those cases with tumor cells with clustering MET-FISH signals in > 10% cells would be considered to be positive and this can be considered as alternative method to address tumor heterogeneity to at least some degree. To further address tumor heterogeneity, we recommend reflex testing by repeating FISH or reflex testing using alternative assays, such as chromogenic in situ hybridization [27] , microarray-based technology [28, 29] , comprehensive molecular characterizations or sequencing based single cell analysis, etc. to accurately determine relevant copy numbers in cells with tumor heterogeneity as previously reported [1, 2, 30] . We are aware of that FISH based testing i.e. the MET-FISH cannot assess genome-wide SCNAs that are often associated with treatment resistance or disease progression in NSCLS, and an integrated genomic approach to accurately assess SCNAs could be utilized in the clinical settings in near future [1, 2] .
Over half of the patients in the current cohort were also assessed for MET expression status by IHC. Our results show that MET overexpression were not associated with disease stages, although patients with METamp did have the higher number of cases with MET overexpression compared with the METneg and METcng subgroups (Supplementary Table 5 ). Unlike the ideal concordance observed HER2 amplification and HER2 overexpression reported previously [31] the overall concordance between MET-CN and MET expression observed in this study was low (~ 45%) which was consistent with what has been reported by others [32] . Similar discordance also has been observed in gastric-intestinal cancer studies by tissue microarray (unpublished data). In addition, the clinical impact of MET overexpression has been controversial, with some studies showing negative impact [33] and others showing the opposite results [32] . Our data did not show independent impact by MET overexpression alone assessed by IHC. We propose that standardized IHC reporting criteria is also needed [34] and that more studies should be conducted to determine if MET protein overexpression assessed by IHC alone is more informative than the MET-CN by FISH [33] .
In conclusion, we suggest that the optimized MET-FISH reporting criteria that are useful for stratifying risk in patients with all stages and histological types of NSCLC. Our results indicated that METamp is strongly associated with stage IV tumors and that MET-FISH testing can identify patients who are eligible for treatment with MET inhibitors [35] . Furthermore, METamp is an independent predictor of poorer prognosis in patients with stages I-III NSCLC. METamp is also a reliable predictor of distant metastases in patients with early stages NSCLC and, such patients may be candidates for more intensive treatments, such as combination therapy using MET inhibitors after surgery. Finally, we found that METcng could represent an independent prognostic group of patients with NSCLC; however, more data are needed to confirm this observation.
PATIENTS AND METHODS
Patients
We retrospectively reviewed the records of all patients with NSCLC who had been tested for MET using FISH between February 1, 2010 and December 31, 2015 at MD Anderson Cancer Center. All patients diagnosed with NSCLC for whose detailed clinicopathologic data are available were included. Patients with ALK receptor tyrosine kinase (ALK), ROS proto-oncogene 1 receptor tyrosine kinase (ROS1), or ret proto-oncogene (RET) gene rearrangements were excluded from the study. Clinical disease stage for all patients was determined using the National Comprehensive Cancer Network staging system for NSCLC [36] . This study was approved by the Institutional Review Board.
FISH analysis
MET-copy-number (MET-CN) status was assessed using a dual-color FISH probe set (CymoGenDX, Irvine, CA) targeting MET and CEP7on formalin-fixed, paraffinembedded tissue sections from tumor specimens following established standard laboratory procedures. MET-CN and the number of CEP7 per nucleus were scored in 60 cells and the mean MET/CEP7 ratio was calculated for each specimen. A subset of FFPE tissue specimens from at least 20 normal individuals was included to establish normal cutoff values following laboratory standard procedures (e.g. chromosome 7 aneuploidy such as monosomy or trisomy/tetrasomy/polysomy 7). The initial reporting criteria used at our institution during the study period, which we designate here as "historical" MET-FISH reporting criteria, classified cases into two categories, METamp and MET-negative (METneg), with a cutoff of MET/CEP7 ratio of 2.0. A sample was considered to have METamp if the mean MET/CEP7 ratio was ≥ 2.0 or if the MET/CEP7 ratio was < 2.0 but the MET-CN was ≥ 20 copies/cell or MET signal clusters were seen in more than10% of tumor cells [24] .
Immunohistochemistry (IHC) analysis
MET immunohistochemical staining (MET-IHC) was evaluated using a Benchmark Ultra Autostainer (Ventana, Tucson, AZ) with anti-total c-MET (SP44) rabbit monoclonal primary antibody (Ventana, Tucson, AZ), following the manufacturer's instructions. Staining was scored by determining the percentage of cells showing weak (1+), moderate (2+), or strong (3+) membranous staining. MET overexpression was considered as positive if ≥ 50% of tumor cells showing cellular membrane staining at an intensity of "2+" or "3+" [37] . Scoring was performed independently by two individuals and any discrepant cases were re-evaluated for the final interpretation.
Statistical analysis
Patient and tumor characteristics, including demographics, tumor type, and MET-CN, were summarized using frequencies, percentages, and distributions. Categorical variables were compared using chi-square and Fisher exact tests, and continuous variables were compared using the Student t test. OS was calculated from the date of first diagnosis to the date of last followup or death of the patient. The log-rank test and KaplanMeier curves were employed to compare OS between subgroups. GraphPad Prism software version 6 (GraphPad Software, La Jolla, CA) was used for the survival analyses. Multivariable analyses, including Cox proportional hazards regression analysis, were performed using SPSS software version 9.3 (SPSS, Inc., Chicago, IL). All tests were 2-sided when appropriate, and differences were considered significant at P <.05. 
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